Barnes-Jewish Hospital
1
19M
1
0.01
- Areas of investment
Summary
Barnes-Jewish Hospital appeared to be the Corporate Investor, which was created in 1902. The fund was located in North America if to be more exact in United States. The leading representative office of defined Corporate Investor is situated in the St Louis.
Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Kereos. Among the most successful fund investment fields, there are Life Science, Therapeutics.
The fund is constantly included in less than 2 deals per year. The common things for fund are deals in the range of 10 - 50 millions dollars. The high activity for fund was in 2005.
The typical case for the fund is to invest in rounds with 10 participants. The meaningful sponsors for the fund in investment in the same round are Triathlon Medical Venture Partners, RiverVest, Prolog Ventures.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Rounds per year
- 0.01
- Investments by industry
- Biotechnology (1)
- Therapeutics (1)
- Health Care (1)
- Life Science (1)
- Investments by region
-
- United States (1)
- Peak activity year
- 2005
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 22
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Kereos | 20 Sep 2005 | Biotechnology, Health Care, Life Science, Therapeutics | Early Stage Venture | 19M | United States, Missouri, City of Saint Louis |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.